{"organizations": [], "uuid": "89dfffbed53730745bc41a4a07c18b34a2126702", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180302.html", "section_title": "Archive News &amp; Video for Friday, 02 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mithra-pharmaceuticals-fy-net-loss/brief-mithra-pharmaceuticals-fy-net-loss-at-35-0-million-euros-idUSFWN1QJ1GR", "country": "US", "domain_rank": 408, "title": "BRIEF-Mithra Pharmaceuticals FY Net Loss At 35.0 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.926, "site_type": "news", "published": "2018-03-02T15:43:00.000+02:00", "replies_count": 0, "uuid": "89dfffbed53730745bc41a4a07c18b34a2126702"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mithra-pharmaceuticals-fy-net-loss/brief-mithra-pharmaceuticals-fy-net-loss-at-35-0-million-euros-idUSFWN1QJ1GR", "ord_in_thread": 0, "title": "BRIEF-Mithra Pharmaceuticals FY Net Loss At 35.0 Million Euros", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "eu & russia", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 2 (Reuters) - MITHRA PHARMACEUTICALS SA:\n* CASH AT DECEMBER 31 2017 WAS EUR 36.2‍​ MILLION VERSUS EUR 45.7 MILLION YEAR AGO\n* FY REVENUE EUR 46.3 MILLION VERSUS EUR 22.5 MILLION YEAR AGO\n* FY REBITDA LOSS EUR 18.1 MILLION VERSUS LOSS OF EUR 34.9 MILLION YEAR AGO\n* FY NET LOSS STABLE AT EUR 35.0 MILLION * TOWARDS END OF Q1/EARLY Q2, TOP-LINE PHASE II DOSE-FINDING RESULTS FOR DONESTA ARE EXPECTED\n* RESULTS OF THE FIRST PIVOTAL ESTELLE STUDY IN THE EU & RUSSIA TO BE AVAILABLE IN Q3 2018\n* RESULTS OF ESTELLE STUDY IN US/CANADA PHASE III RESULTS TO BE PUBLISHED IN Q1 2019\n* EUROPEAN APPROVAL CAN ALREADY BE EXPECTED IN Q2/Q3 2018 FOR MYRING\n* FOR MYRING MAYNE PHARMA MAKING SIGNIFICANT PROGRESS FOR THE US APPROVAL AND LAUNCH, EXPECTED IN H1 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-02T15:43:00.000+02:00", "crawled": "2018-03-03T17:25:34.000+02:00", "highlightTitle": ""}